Basit öğe kaydını göster

dc.contributor.authorTukel, Rasit
dc.date.accessioned2021-03-05T10:41:56Z
dc.date.available2021-03-05T10:41:56Z
dc.identifier.citationTukel R., "The role of anticonvulsants in treatment-resistant anxiety disorders", KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, cilt.19, 2009
dc.identifier.issn1017-7833
dc.identifier.othervv_1032021
dc.identifier.otherav_a4756cd1-8e3c-4362-8cc6-fe6efcbc30bb
dc.identifier.urihttp://hdl.handle.net/20.500.12627/110019
dc.description.abstractAntidepressants are the first-line pharmacological treatment approach for the anxiety disorders. Other pharmacotherapy options for anxiety disorders include benzodiazepines, atypical antipsychotics, and anticonvulsants. Evidence provided by double-blind, placebo-controlled trials demonstrates the effectiveness of pregabalin and valproic acid for generalized anxiety disorder, pregabalin and gabapentin for social anxiety disorder, valproic acid for panic disorder, and lamotrigine for posttraumatic stress disorder. Further research is needed to determine the efficacy of anticonvulsants for the treatment-resistant anxiety disorder patients.
dc.language.isoeng
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectKlinik Tıp (MED)
dc.subjectSağlık Bilimleri
dc.subjectPsikiyatri
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.titleThe role of anticonvulsants in treatment-resistant anxiety disorders
dc.typeMakale
dc.relation.journalKLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY
dc.contributor.departmentİstanbul Üniversitesi , İstanbul Tıp Fakültesi , Psikiyatri
dc.identifier.volume19
dc.contributor.firstauthorID191445


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster